论文部分内容阅读
目的 :合成阿霉素聚氰基丙烯酸异丁酯纳米粒 (DOX PIBCA NP)并检测其相关参数 ,观察其对多药耐受相关蛋白 (MRP)介导的人膀胱癌细胞多药耐药 (MDR)的逆转。方法 :以乳液聚合法合成阿霉素纳米粒 ,透射电镜计算粒径 ,分光光度法计算包封率 ,MTT法观察MDR的逆转。结果 :阿霉素纳米粒平均粒径 98.5± 3.6 7nm ,包封率 95 % ,其对耐药、敏感株的细胞毒作用差异无显著性意义 (P >0 .0 5 ) ,耐药株对阿霉素纳米粒较对阿霉素敏感 4 .9倍 (P <0 .0 5 )。结论 :阿霉素纳米粒可有效逆转MRP介导的MDR。
OBJECTIVE: To synthesize doxorubicin-loaded polybutylcyanoacrylate nanoparticles (DOX PIBCA NP) and to detect its related parameters, and to observe its effect on multidrug resistance-associated protein (MRP) -mediated multidrug resistance in human bladder cancer cells MDR) reversal. Methods: The doxorubicin nanoparticles were synthesized by emulsion polymerization. The particle size was calculated by transmission electron microscopy. The encapsulation efficiency was calculated by spectrophotometry. The reversal of MDR was observed by MTT assay. Results: The average particle size of doxorubicin nanoparticles was 98.5 ± 3.6 7nm with the encapsulation efficiency of 95%. There was no significant difference in the cytotoxicity between the drug-resistant and susceptible strains (P> 0.05) Adriamycin nanoparticles were 4.9 times more sensitive to doxorubicin (P <0.05). Conclusion: Adriamycin nanoparticles can effectively reverse MRP-mediated MDR.